Atopic dermatitis, also known as eczema, is a condition in which skin becomes dry, itchy, and inflamed, which leads to redness, swelling, scaling, and crusting. Atopic dermatitis is commonly found in children under one year. The exact cause of atopic dermatitis is undiscovered, but it is believed that it includes genetics, environmental exposure, immune system dysfunction, and problem with skin permeability. Dry climate is also a major cause of atopic dermatitis. This disease is non-contagious and easily diagnosed with signs and symptoms such as swelling and redness of skin. Many people with atopic dermatitis develop asthma and hay fever. Atopic dermatitis treatment involves photo therapy, steroid pills, calcineurin inhibitors ointment, biologic agents such as immunologic, monoclonal antibody, and dietary changes in case of food allergy.

Request For A Sample Copy Of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/712

Topical steroids and development of new drugs fuel the atopic dermatitis drug market

Atopic dermatitis treatment majorly relies on topical steroids and hence the segment holds the largest market share. A lukewarm bath followed by the application of moisturizer helps in the treatment of atopic dermatitis. Immunomodulators and pimecrolimus are also used for the treatment of atopic dermatitis. According to the American Academy of Dermatology, in 2016, there were around 28 million people of all age groups affected by atopic dermatitis in the U.S. The expected launch of dupilumab, monoclonal antibody developed by Sanofi and Regeneron Pharmaceuticals Inc. in 2017, which is approved by FDA for the treatment of atopic dermatitis plays a major role in the treatment of the disease and supports the growth of atopic dermatitis drug market.

Atopic Dermatitis Drug Market Taxonomy

By End User;

Hospitals

Clinics

Research Labs

By Route of Administration;

Injectable

Oral

Topical

By Therapy;

Photo Therapy

Directed Therapy

Developed regions support the growth of atopic dermatitis drug market

On the basis of geography, the global atopic dermatitis drug market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the atopic dermatitis drug market due to increasing number of atopic dermatitis cases and high R&D investment for the development of atopic dermatitis drug. The increase in food and skin allergies raised the atopic dermatitis cases in infants, which in turn fuels the atopic dermatitis drug market growth.

Key Players in the Global Atopic Dermatitis Drug Market

Major players in the market use different strategies such as mergers and acquisitions in order to acquire high market share and attain a competitive edge. In 2016, Novartis AG acquired Ziarco, which adds oral atopic dermatitis drug to its product pipeline. Pfizer acquired Anacor Pharmaceuticals in 2016 allowing access to non-steroidal topical gel, crisaborole, approved by FDA for atopic dermatitis treatment. Some of the key players in the market are Bayer Healthcare, Valent Pharmaceutical Inc., Astellas Pharma Inc., Meda AB, and Novartis AG.

Click To Read More On Atopic Dermatitis Drug Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.